Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future

Lung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered a...

Descripción completa

Detalles Bibliográficos
Autores principales: Szeto, Chun Ho, Shalata, Walid, Yakobson, Alexander, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658154/
https://www.ncbi.nlm.nih.gov/pubmed/34884316
http://dx.doi.org/10.3390/jcm10235614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658154/
https://www.ncbi.nlm.nih.gov/pubmed/34884316
http://dx.doi.org/10.3390/jcm10235614

Ejemplares similares